6-APB: Difference between revisions

Line 118:

===Long-term health concerns===

The neurotoxicity of 6-APB is controversial. ~~While~~ specifically designed to be less neurotoxic than MDA or MDMA through the avoidance of producing certain metabolic byproducts thought to underlie their toxicity, scientific study has come to the general consensus that, although it is physically safe to try in a responsible context, the administration of repeated or high dosages of 6-APB is most certainly neurotoxic in some form, often manifesting as deficits in cognitive, affective and psychomotor function.

The neurotoxicity of 6-APB is controversial. It was specifically designed to be less neurotoxic than MDA or MDMA through the avoidance of producing certain metabolic byproducts thought to underlie their toxicity. However, scientific study has come to the general consensus that, although it is physically safe to try in a responsible context, the administration of repeated or high dosages of 6-APB is most certainly neurotoxic in some form, often manifesting as deficits in cognitive, affective and psychomotor function.

As with MDMA, long-term heavy use of 6-APB is likely cardiotoxic and thought to lead to valvulopathy through its actions on the 5-HT2B receptor.<ref> Drug-induced Valvulopathy: An Update | tpx.sagepub.com/content/38/6/837.full</ref> ~~In one study, 28% of long-term users (2-3 doses per week for a mean of 6 years with a mean of age 24.3 years) had developed clinically evident valvular heart disease.~~<ref>Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/17950805</ref>

As with MDMA, long-term heavy use of 6-APB is likely cardiotoxic and thought to lead to valvulopathy through its actions on the 5-HT2B receptor.<ref> Drug-induced Valvulopathy: An Update | tpx.sagepub.com/content/38/6/837.full</ref><ref>Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/17950805</ref>

It is strongly recommended that one use [[responsible drug use|harm reduction practices]] when using this drug.

@@ Line 118: / Line 118: @@
 ===Long-term health concerns===
-The neurotoxicity of 6-APB is controversial. While specifically designed to be less neurotoxic than MDA or MDMA through the avoidance of producing certain metabolic byproducts thought to underlie their toxicity, scientific study has come to the general consensus that, although it is physically safe to try in a responsible context, the administration of repeated or high dosages of 6-APB is most certainly neurotoxic in some form, often manifesting as deficits in cognitive, affective and psychomotor function.
+The neurotoxicity of 6-APB is controversial. It was specifically designed to be less neurotoxic than MDA or MDMA through the avoidance of producing certain metabolic byproducts thought to underlie their toxicity. However, scientific study has come to the general consensus that, although it is physically safe to try in a responsible context, the administration of repeated or high dosages of 6-APB is most certainly neurotoxic in some form, often manifesting as deficits in cognitive, affective and psychomotor function.
-As with MDMA, long-term heavy use of 6-APB is likely cardiotoxic and thought to lead to valvulopathy through its actions on the 5-HT2B receptor.<ref> Drug-induced Valvulopathy: An Update | tpx.sagepub.com/content/38/6/837.full</ref> In one study, 28% of long-term users (2-3 doses per week for a mean of 6 years with a mean of age 24.3 years) had developed clinically evident valvular heart disease.<ref>Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/17950805</ref>
+As with MDMA, long-term heavy use of 6-APB is likely cardiotoxic and thought to lead to valvulopathy through its actions on the 5-HT2B receptor.<ref> Drug-induced Valvulopathy: An Update | tpx.sagepub.com/content/38/6/837.full</ref><ref>Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/17950805</ref>
 It is strongly recommended that one use [[responsible drug use|harm reduction practices]] when using this drug.